Pentapeptide-3V: Neuromuscular Transmission and Skin Texture

Pentapeptide-3V (Vialox) is a synthetic peptide derived from snake venom and comprises a five-amino-acid sequence (Gly-Pro-Arg-Pro-Ala, or GPRPA).⁽¹⁾

As per the researchers, it is suggested that this peptide acts as a competitive antagonist at the nicotinic acetylcholine receptors (AChRs) located on the postsynaptic membrane of muscle cells. These receptors are considered integral to signal transmission between nerve and muscle cells, facilitating muscle contraction. Pentapeptide-3V is suggested to interfere with this process, potentially mimicking the effects of certain neuromuscular blockers believed to induce muscle relaxation. Its unique mode of action may offer insights into reducing the development of wrinkles along the stratum corneum by relaxing localized muscular contractions.

Image 1: Chemical Structure of Pentapeptide-3V (Vialox)

Normally, acetylcholine, a neurotransmitter released from nerve endings, is believed to bind to nicotinic acetylcholine receptors to trigger sodium ion channel opening, leading to depolarization and subsequent muscle contraction. Pentapeptide-3V, as a non-depolarizing neuromuscular blocker, may compete with acetylcholine for binding at these receptor sites. Unlike acetylcholine, Pentapeptide-3V does not appear to initiate receptor activity, potentially blocking signal transmission and preventing muscle contraction.^{( 2,3)}

This inhibitory potential appears to be akin to the muscle-relaxing properties of tubocurarine, a natural alkaloid derived from plants like Chondrodendron tomentosum.⁽⁴⁾ By maintaining the muscles in a relaxed state, Pentapeptide-3V potentially reduces dynamic wrinkles on the skin.

 

Research

Pentapeptide-3V Peptide and Wrinkle Formation, Skin Texture

Scientific investigations into Pentapeptide-3V have evaluated its potential to possibly mitigate wrinkle formation and improve skin texture by targeting neuromuscular signal transmission. By acting as a competitive antagonist to nicotinic acetylcholine receptors, Pentapeptide-3V may “soften wrinkles and reduce skin roughness”.⁽⁴⁾ Notably, researchers report that Pentapeptide-3V exhibits a short half-life, potentially minimizing the likelihood of prolonged systemic exposure or unanticipated action.

Other experimental data suggest that Pentapeptide-3V may significantly reduce muscle contractions. Studies have reported a 71% reduction in muscle activity within one minute of exposure, followed by a 58% reduction after two hours. These findings support the hypothesis that the peptide may lead to decreased muscle activity, and thus shallower wrinkle depth in the skin surface.

Further research has examined the peptide’s efficacy in long-term exposure. Findings suggest that a 49% reduction in wrinkle size and a 47% increase in skin consistency after 28 days of consistent exposure.⁽⁵⁾

Pentapeptide-3V Peptide and Neuromuscular Transmission

Pentapeptide-3V appears to have garnered scientific interest due to its proposed ability to disrupt nerve-muscle communication. Unlike other antagonists of nicotinic acetylcholine receptors (AChR), Pentapeptide-3V appears to act exclusively on peripheral AChR, with minimal impact on central neuronal receptors as suggested by animal studies. Researchers hypothesize that Pentapeptide-3V might be relevant to research focused on addressing certain spastic conditions, including migraines and muscle spasms.

Pentapeptide-3V is suggested to interfere with signal transmission between neurons and muscles by acting as an antagonist of the acetylcholine receptor. It appears to block nerve signals at the post-synaptic membrane, leading to muscle relaxation. Normally, when a nerve’s axon releases acetylcholine, these signals appear to travel to the neuromuscular junction and bind to receptors on the muscle, facilitating the release of sodium ions. This process may result in depolarization, generating the electrical pulse responsible for muscle contraction and wrinkle formation.

Pentapeptide-3V is studied for its potential to halt this process by binding to AChR, thereby preventing acetylcholine from attaching to these receptors. This blockade is thought to reduce both the frequency and intensity of muscular contractions, similar to the effects induced by botulinum toxin, tubocurarine, and curare toxin. The consequent partial paralysis of muscles leads to forced relaxation.

 
NOTE: These products are intended for laboratory research use only. This peptide is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.

 

References:

1. National Center for Biotechnology Information (2024). PubChem Compound Summary for CID 67073230, Vialox. Retrieved August 4, 2024 from https://pubchem.ncbi.nlm.nih.gov/compound/Vialox.
2. Lupo, M. P., & Cole, A. L. (2007). Cosmeceutical peptides. Dermatologic therapy, 20(5), 343-349. https://pubmed.ncbi.nlm.nih.gov/18045359/
3. Gorouhi, F., & Maibach, H. I. (2009). Role of peptides in preventing or treating aged skin. International journal of cosmetic science, 31(5), 327-345. https://pubmed.ncbi.nlm.nih.gov/19570099/
4. Satriyasa B. K. (2019). Botulinum toxin (Botox) A for reducing the appearance of facial wrinkles: a literature review of clinical use and pharmacological aspect. Clinical, cosmetic and investigational dermatology, 12, 223–228. https://doi.org/10.2147/CCID.S202919
5. Lebedev DS, Kryukova EV, Ivanov IA, Egorova NS, Timofeev ND, Spirova EN, Tufanova EY, Siniavin AE, Kudryavtsev DS, Kasheverov IE, Zouridakis M, Katsarava R, Zavradashvili N, Iagorshvili I, Tzartos SJ, Tsetlin VI. Oligoarginine Peptides, a New Family of Nicotinic Acetylcholine Receptor Inhibitors. Mol Pharmacol. 2019 Nov;96(5):664-673. doi: 10.1124/mol.119.117713. Epub 2019 Sep 6. PMID: 31492697. https://pubmed.ncbi.nlm.nih.gov/31492697/
6. Image 1 source: National Center for Biotechnology Information (2024). PubChem Compound Summary for CID 67073230, Vialox. Retrieved August 4, 2024 from https://pubchem.ncbi.nlm.nih.gov/compound/Vialox.